Madrigal Pharmaceuticals

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Our lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist targeting key causes of NASH. Currently in Phase 3 clinical studies, resmetirom aims to demonstrate multiple benefits for NASH patients. Join our team and contribute to groundbreaking advancements in liver disease treatment.